Biotech firms have been increasingly directing capital toward oncology therapeutics in recent years, reflecting a structural shift as companies recognize the significant commercial potential of ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce ...

Diversification via an ETF can help biotech investors avoid boom-or-bust volatility while still capitalizing on long-term growth trends.

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ...

Payable Sep 25; for shareholders of record Sep 21; ex-div Sep 21. More on Invesco Nasdaq Biotechnology ETF Seeking Alpha’s Quant Rating on Invesco Nasdaq Biotechnology ETF Dividend scorecard for Inves ...

PBE offers higher income and stronger returns, while RSPH provides broader diversification with lower costs and drawdown risk ...

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion of the S&P 500, started in January ...

VanEck Biotech ETF is a Buy, offering concentrated exposure to leading biotech firms entering a new growth cycle. BBH’s top holdings—Amgen, Gilead, and Vertex—drive capital appreciation through ...

The Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) offers lower costs and broader market diversification, while the VanEck Biotech ETF (NASDAQ:BBH) provides a more concentrated in ...

Detailed price information for S&P Biotech SPDR (XBI-A) from The Globe and Mail including charting and trades.

The investment seeks is to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index (the “underlying index”) by selling options on leveraged ...

Following the sale, iShares Biotechnology ETF is comprised 2.67% of DAFNA Capital’s 13F reportable assets under management. Top five holdings after the filing: NASDAQ:RVMD: $48.15 million (11.3% of ...